Sun Pharmaceutical Industries

207 articles with Sun Pharmaceutical Industries

• Sun Pharma Announces 5-Year Sustained Efficacy and Safety Results for ILUMYA® (tildrakizumab-asmn) in Patients with Moderate-to-Severe Plaque Psoriasis

  10/31/2020

  ILUMYA is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis

• Sun Pharmaceutical Industries, Inc. Issues Voluntary Nationwide Recall of RIOMET ER™ (metformin hydrochloride for extended-release oral suspension) Due to N-Nitrosodimethylamine (NDMA) Content Above the Acceptable Daily Intake (ADI) Limit

  9/23/2020

  Sun Pharmaceutical Industries, Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. is voluntarily recalling one lot of RIOMET ER™, 500 mg per 5 mL to the consumer level.

• Orexo commences patent infringement litigation against Sun Pharmaceutical

  9/14/2020

  Orexo AB (publ.),  (STO:ORX) (OTCQX:ORXOY) today announces it has filed a patent infringement action in the United States District Court for the District of New Jersey with docket number 3:20-cv-12588, against Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma Global, Inc., and Sun Pharmaceutical Indu

• Orexo receives paragraph IV Notice Letter for ZUBSOLV® in the US

  8/10/2020

  Orexo AB, announces it has received a "paragraph IV" patent certification notice from Sun Pharmaceutical Industries Limited.

• Sun Pharma Presents ODOMZO® and LEVULAN® KERASTICK® + BLU-U® Data, Offering Clinical Insights for Treating People with or at Risk of Skin Cancer

  6/12/2020

  Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" including its subsidiaries and/or associate companies) today announced that one of its wholly-owned subsidiaries presented data analyses for two of its specialty medicines – ODOMZO® (sonidegib) and LEVULAN® KERASTICK®

• Sun Pharma Announces Long-term Insights into the Clinical Use of ILUMYA™ (tildrakizumab-asmn) in a Cross Section of People Living with Moderate-to-Severe Plaque Psoriasis

  6/12/2020

  Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" including its subsidiaries and/or associate companies) today announced that one of its wholly owned subsidiaries presented further evidence of the long-term use and cost-effectiveness of ILUMYATM

• Sun Pharma Plans to Present Clinical Insights from 25 Data Abstracts Across its Dermatology Portfolio at the 2020 AAD Virtual Meeting Experience

  6/11/2020

  The breadth of continued research in plaque psoriasis, psoriatic arthritis, basal cell carcinoma, and actinic keratoses underscores Sun Pharma's commitment to dermatology HCPs and patients   [11-June-2020]   PRINCETON, N.J. , June 11, 2020 /PRNewswire/ -- Sun Pharmaceutical Industries Inc., USA (SPII) "Sun Pharma" today announced 25 data abstracts from its dermatology p

• Sun Pharmaceutical Industries, Inc. Donates 2.5 Million Hydroxychloroquine Sulfate Tablets in the U.S. For Potential COVID-19 Treatment

  3/27/2020

  Sun Pharmaceutical Industries, Inc., USA, (SPII),a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. (‘together Sun Pharma,’ Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715), announced that it has donated 2.5 million hydroxychloroquine sulfate tablets for use in the United States.

• Sun Pharma Launches RIOMET ER Oral Suspension in the U.S.

  2/26/2020

  RIOMET ER™ (metformin hydrochloride for extended-release oral suspension) is the first and only U.S. FDA-approved extended-release liquid formulation of metformin

• Sun Pharma Launches New Ad Campaign to Raise Awareness of Acne and its Impact on Everyday Life

  2/10/2020

  Feb. 10, 2020 12:45 UTC “Take on Acne” ad campaign emphasizes the discomfort and disruption caused by acne, especially among teens and young adults PRINCETON, N.J.--( BUSINESS WIRE )-- Sun Dermatology, a division of Sun Pharmaceutical Industries, Inc., USA, which is a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. (together “Sun Pharma”), today announced the launch of Take on Acne – a new advertising campaign designed to raise awareness of the profound imp

• Cipher Pharmaceuticals Provides Update on Absorica Brand Extension Program with Sun Pharmaceutical

  2/6/2020

  Cipher Pharmaceuticals Inc. is pleased to announce that Sun Pharmaceutical Industries Ltd., the Company's U.S. marketing partner for Absorica®, has launched ABSORICA LD™ capsules in the U.S for the management of severe recalcitrant nodular acne in patients 12 years of age and older.

• Sun Pharma Introduces ABSORICA LD™ (Isotretinoin) Capsules for Management of Severe Recalcitrant Nodular Acne in the U.S.

  2/4/2020

  Sun Pharmaceutical Industries Ltd. announced that one of its wholly owned subsidiaries has launched ABSORICA LD™ capsules in U.S. for the management of severe recalcitrant nodular acne in patients 12 years of age and older.

• Rockwell Medical, Inc. Enters into Exclusive License and Supply Agreements with Sun Pharma for the Rights to Commercialize Triferic® in India- Sizable and growing market opportunity with 120,000+ patients receiving hemodialysis annually –

  1/15/2020

  Rockwell Medical, Inc. announced that it has entered into license and supply agreements with a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd., for the rights to commercialize Triferic in India.

• Sun Pharma Launches Drizalma Sprinkle in the U.S.

  10/16/2019

  Sun Pharmaceutical Industries Ltd. announced that one of its wholly owned subsidiaries has launched Drizalma Sprinkle™ in the U.S. for oral use.

• Sun Pharma Launches CEQUA for the Treatment of Dry Eye Disease in the U.S.

  10/14/2019

  CEQUA™ (cyclosporine ophthalmic solution) 0.09% for topical ophthalmic use is the first and only approved cyclosporine treatment delivered with NCELL™ technology

• Sun Pharma Introduces Access Program for Patients Prescribed XELPROS in the U.S.

  7/17/2019

  XELPROS™ 0.005%, the only FDA-approved Benzalkonium chloride-free formulation of latanaprost, was recently launched by Sun Pharma for the treatment of Glaucoma or Ocular Hypertension

• Sun Pharma Launches Ezallor Sprinkle (Rosuvastatin) in the U.S. for People Who Have Difficulty Swallowing

  7/15/2019

  Sun Pharmaceutical Industries Ltd. announced the U.S. launch of Ezallor Sprinkle™ capsules for the treatment of three types of elevated lipid disorders in people who have difficulty swallowing, a problem that is estimated to affect approximately 30-35% of long-term care residents.

• Sun Pharma Announces Late-Breaking Phase 2 Data Showing Potential of ILUMYA™ (tildrakizumab-asmn) to Improve Joint and Skin Symptoms of Psoriatic Arthritis

  6/14/2019

  Over 71% of Patients Treated with ILUMYA™ Achieved ACR20 Response After 24 Weeks, with Significant Improvement as Early as 8 Weeks MUMB

• Sun Pharma Launches Ready-to-Infuse INFUGEM in the U.S.

  4/8/2019

  Use of ready-to-infuse bags eliminates steps in the complex chemotherapy preparation process, reducing exposure and mitigating inherent provider and patient safety risks

• Sun Pharmaceutical Industries Inc. Announces Plans to Present 19 Data Abstracts on ILUMYA™ for Moderate-to-Severe Plaque Psoriasis at American Academy of Dermatology 2019 Annual Meeting

  2/27/2019

  Sun Pharmaceutical Industries Inc., USA (SPII) today announced that it plans to present 19 abstracts featuring data on ILUMYA™ (tildrakizumab-asmn), a prescription medicine used to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic or phototherapy, at the 77th Annual Meeting of the American Academy of Dermatology (AAD) from March 1 – 5 in Washington, DC.